Synertech-Dosagen Plant Negotiation
Synertech-Dosagen Plant Negotiation
Purchasing Dosagen's plant offers several benefits, including the facility being operational and already possessing FDA approval, which significantly shortens the timeframe needed to begin production . Additionally, the existing experienced workforce could reduce hiring and training costs . However, it is located 70 miles from Synertech's HQ, presenting logistical challenges . Building a new plant would allow Synertech to control the plant's design and location, minimizing logistic issues, but it would require significant time and resources to gain FDA approval and establish operations .
Synertech's significant cash reserves position them as a strong buyer capable of making an immediate cash offer, which could be appealing to Dosagen, especially if Dosagen seeks quick liquidity . This financial strength allows Synertech to potentially secure favorable terms without the constraints of financing conditions . However, Synertech must also consider opportunity costs and ensure the expense aligns with their strategic goals.
The Dosagen CFO's leverage includes an operational factory with FDA approval and an experienced workforce . Recognizing this, Synertech might focus on negotiating price adjustments by emphasizing the Dosagen plant's distance from Synertech's HQ and the declining real estate market . This awareness allows Synertech to argue for a price reduction while acknowledging the operational benefits of acquiring a ready-to-use facility.
The Dosagen plant's distance of 70 miles from Synertech's HQ presents a logistical challenge that could be used as a point in negotiations to justify a lower purchase price . This distance impacts operational efficiency, potential transport costs, and coordination with the research group located at HQ. Synertech may leverage this disadvantage to negotiate terms that mitigate the impact or reduce the cost outlay for acquiring the plant, balancing the operational readiness of the site against its location.
Synertech can counter Dosagen's strengths, such as an operational plant and experienced workforce, by emphasizing the benefits and strategic fit of building a new facility closer to Synertech's HQ . Highlighting the time and logistical savings associated with a nearby location and the potential for a customized solution may neutralize Dosagen's operational advantage. Furthermore, framing these points around the broader strategic context and suggesting patience for long-term gains could shift perceived negotiation leverage.
Synertech's BATNA involves building a new plant for $25 million, serving as a cap on their willingness to pay for Dosagen's plant . This alternative affects negotiations by providing Synertech with a fallback plan, hence strengthening their bargaining position as they aren't dependent on the deal going through. Understanding their BATNA allows Synertech to push against high demands from Dosagen, knowing they have other options if negotiations fall through.
Synertech plans to make an initial offer of $13 million to anchor the negotiation at a low starting point . This strategy draws on psychological anchoring effects, aiming to frame the negotiation around a favorable price point for Synertech. By starting low, they create room to negotiate upwards while encouraging Dosagen to stay within a lower price range. The success of this approach depends on Dosagen's negotiation expectations and urgency to sell.
Market value appraisals provide a baseline for negotiations by indicating the property's potential worth . Synertech must consider the plant's appraisal from three years ago ($27 million) and the recent market decline of 20% to estimate a current market value closer to $21 million . However, a similar plant sold for $13 million nine months ago, complicating the appraisal relevance. Synertech must weigh these factors alongside strategic considerations like operational readiness and proximity to HQ.
Building a new plant risks include significant delays in production (estimated one year if all goes well), additional costs for gaining FDA approval, possible construction and operational setbacks, and higher initial costs . Moreover, the time delay could result in lost market opportunities and competitive disadvantage . These risks must be balanced against the long-term strategic benefits of having a plant in close proximity to Synertech's HQ.
The 20% decline in real estate markets since the last appraisal provides Synertech with leverage to argue for a reduced purchase price on the Dosagen plant . This decline indicates a decrease in market value from the previous appraisal of $27 million to a lower, realistic figure, around $21 million . Highlighting this economic factor helps justify a negotiation stance that aligns closer to the recent sale of a similar plant for $13 million.





